TuHURA Biosciences, Inc.
NASDAQ:HURABiotechnology
+$0.14 today
- Market cap
- $87.31M
- Beta
- 0.01
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.52
Volume 0.19M
Average 0.85M
HURA Interest Expense
Cost of servicing the company's debt during the period.
TuHURA Biosciences, Inc.NASDAQ: HURA
Interest Expense · Q1 FY2026 · quarter ended Mar 2026
Interest expense remains negative
Q1 FY2026 interest expense was $27.97K, compared with $0 a year earlier. Trailing-twelve-month interest expense was $653.26K.
Context
- Interest expense increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly interest expense holds near $27.97K or moves back toward the trailing-twelve-month quarterly average of $163.31K.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Expense history
USD · from the income statement
- Latest · FY2025
- 625.28K USD
- Year-over-year change
- -84.9%
- 4-year CAGR
- -0.2%
| Period | Period end | Interest Expense | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 625.28K | -84.9% |
| FY2024 | 2024-12-31 | 4.14M | +22044.2% |
| FY2023 | 2023-12-31 | 18.69K | — |
| FY2022 | 2022-12-31 | 0 | -100.0% |
| FY2021 | 2021-12-31 | 629.29K | — |
Interest Expense vs competitors
How HURA compares with its peers on the latest reported figures
- HURA's LTM Mar 2026 interest expense of $653.26K is the 4th highest of the 9 companies compared; the peer median is $6.5K.
- Its year-over-year change of -83.2% is the 5th highest of 6, against a peer median of -35.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $57.17M | -43.4% | -3.7% | 46.2% | |
| LTM Mar 2026 | $4.27M | +4.4% | — | — | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $2.15M | +56.9% | +446.1% | 18.0% |
| LTM Mar 2026 | $653.26K | -83.2% | — | — | |
| LTM Mar 2026 | $13K | -35.0% | -22.6% | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | -100.0% | — | 0.0% | |
| Peer median (excluding HURA) | $6.5K | -35.0% | -3.7% | 0.0% | |
Competitors are the stored peer set for HURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 60K | 60K | 55K | 0 | 0 |
| Gross Profit | (60K) | (60K) | (55K) | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 15.17M | 9.31M | 2.66M | 13.34M | 20.53M |
| Selling, General & Admin | 7.45M | 5.43M | 5.73M | 3.87M | 7.58M |
| Operating Expenses | 22.62M | 14.74M | 8.4M | 17.65M | 31.8M |
| Depreciation & Amortization | 60K | 60K | 55K | 116.71K | 71.27K |
| EBITDA | (21.97M) | (14.59M) | (8.27M) | (17.43M) | (29.36M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (22.68M) | (14.8M) | (8.45M) | (17.65M) | (31.8M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 57.35K | 89.67K | 361.63K | 136.23K |
| Interest Expense | 629.29K | 0 | 18.69K | 4.14M | 625.28K |
| Other Income / Expenses | 21K | 147K | 131K | (4.03M) | 1.74M |
| Income Before Tax | (22.66M) | (14.65M) | (8.32M) | (21.68M) | (30.06M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (22.66M) | (14.65M) | (8.32M) | (21.68M) | (30.06M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (903.04) | (324.48) | (11.29) | (1.21) | (0.63) |
| EPS (Diluted) | (903.04) | (324.48) | (11.29) | (1.21) | (0.63) |
| Weighted Avg Shares | 27.83K | 46.29K | 752.91K | 18.66M | 47.93M |
| Weighted Avg Shares (Diluted) | 27.83K | 46.29K | 752.91K | 18.66M | 47.93M |
TuHURA Biosciences, Inc.
NASDAQ:HURA
Intrinsic Alpha fair value
Locked
Current Price
$1.37
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.